Oncogenic KRAS effector USP13 promotes metastasis in non-small cell lung cancer through deubiquitinating β-catenin
Summary: KRAS mutations are frequently detected in non-small cell lung cancers (NSCLCs). Although covalent KRASG12C inhibitors have been developed to treat KRASG12C-mutant cancers, effective treatments are still lacking for other KRAS-mutant NSCLCs. Thus, identifying a KRAS effector that confers poo...
Main Authors: | Yanguan Guo, Jiaxin Tian, Yongjian Guo, Cong Wang, Congcong Chen, Songwang Cai, Wenliang Yu, Binghe Sun, Jin Yan, Zhonghua Li, Jun Fan, Qi Qi, Dongmei Zhang, Weilin Jin, Zichun Hua, Guo Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-12-01
|
Series: | Cell Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2211124723015231 |
Similar Items
-
Differential Effector Engagement by Oncogenic KRAS
by: Tina L. Yuan, et al.
Published: (2018-02-01) -
Function of Deubiquitinating Enzyme USP14 as Oncogene in Different Types of Cancer
by: Ying Zhu, et al.
Published: (2016-03-01) -
The deubiquitinase USP7 promotes HNSCC progression via deubiquitinating and stabilizing TAZ
by: Jin Li, et al.
Published: (2022-08-01) -
Blockade of the deubiquitinating enzyme USP48 degrades oncogenic HMGA2 and inhibits colorectal cancer invasion and metastasis
by: Can Cheng, et al.
Published: (2024-04-01) -
USP13 negatively regulates antiviral responses by deubiquitinating STING
by: He Sun, et al.
Published: (2017-05-01)